目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 34)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONS COVERED
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 KEY STAKEHOLDERS
1.5 SUMMARY OF CHANGES
1.6 RECESSION IMPACT

2 RESEARCH METHODOLOGY (Page No. - 41)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY RESEARCH
2.1.2 PRIMARY RESEARCH
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 VENDOR REVENUE MAPPING-BASED MARKET ESTIMATION
2.2.2 END-USER ASSESSMENT-BASED MARKET ESTIMATION
FIGURE 5 POINT OF CARE DIAGNOSTICS MARKET: MARKET SIZE ESTIMATION METHODOLOGY
2.2.3 PRIMARY RESEARCH VALIDATION
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 6 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH LIMITATIONS
2.5 RECESSION IMPACT ANALYSIS
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)

3 EXECUTIVE SUMMARY (Page No. - 52)
FIGURE 7 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
FIGURE 8 POINT OF CARE DIAGNOSTICS INDUSTRY, BY PLATFORM, 2023 VS. 2028 (USD MILLION)
FIGURE 9 MARKET, BY MODE OF PURCHASE, 2023 VS. 2028 (USD MILLION)
FIGURE 10 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 11 GEOGRAPHIC SNAPSHOT OF MARKET

4 PREMIUM INSIGHTS (Page No. - 56)
4.1 POINT OF CARE DIAGNOSTICS MARKET OVERVIEW
FIGURE 12 INCREASING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
4.2 POINT OF CARE DIAGNOSTICS INDUSTRY, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
FIGURE 13 INFECTIOUS DISEASE TESTING PRODUCTS TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
4.3 MARKET, BY MODE OF PURCHASE (2022)
FIGURE 14 OTC TESTING PRODUCTS ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
4.4 MARKET, BY PLATFORM, 2023 VS. 2028
FIGURE 15 LATERAL FLOW ASSAYS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.5 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 16 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 60)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 17 POINT OF CARE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence of infectious diseases
FIGURE 18 REGIONAL INCIDENCE OF HIV (2022)
5.2.1.2 Increasing prevalence of target conditions
5.2.1.3 Favorable government initiatives for POC testing
5.2.1.4 Rising number of CLIA-waived POC tests
TABLE 2 RECENT WAIVERS FOR PRODUCTS
5.2.2 RESTRAINTS
5.2.2.1 Pricing pressure on POC manufacturers
5.2.2.2 Stringent regulatory approval process for product commercialization
5.2.3 OPPORTUNITIES
5.2.3.1 High growth potential of emerging markets
5.2.3.2 Decentralization of healthcare
5.2.3.3 Innovative product development
5.2.4 CHALLENGES
5.2.4.1 Inadequate standardization with centralized lab methods
5.2.4.2 Limited awareness in emerging markets
5.2.4.3 Premium pricing of novel platforms
5.3 TECHNOLOGY ANALYSIS
5.3.1 POC TESTS WITH MULTIPLEXING CAPABILITIES
5.3.2 STROKE/CARDIAC MARKERS
5.3.3 THYROID TESTING
5.3.4 DNA TESTING
5.3.5 ENDOCRINE TESTING
5.3.6 RESPIRATORY DIAGNOSTICS
5.4 REGULATORY LANDSCAPE
TABLE 3 REGULATORY BODIES AND GOVERNMENT AGENCIES
5.4.1 KEY REGULATORY GUIDELINES
5.4.1.1 US
FIGURE 19 US: REGULATORY PROCESS FOR IVD DEVICES
5.4.1.2 Canada
FIGURE 20 CANADA: REGULATORY PROCESS FOR IVD DEVICES
5.4.1.3 Europe
FIGURE 21 EUROPE: REGULATORY PROCESS FOR IVD DEVICES
5.4.1.4 Japan
FIGURE 22 JAPAN: REGULATORY PROCESS FOR IVD DEVICES
5.4.1.5 China
TABLE 4 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.4.1.6 India
FIGURE 23 INDIA: REGULATORY PROCESS FOR IVD DEVICES
5.4.1.7 Brazil
FIGURE 24 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
5.5 VALUE CHAIN ANALYSIS
FIGURE 25 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING REGULATION & DISTRIBUTION STAGES
5.6 SUPPLY CHAIN ANALYSIS
5.6.1 PROMINENT COMPANIES
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES
5.6.3 END USERS
FIGURE 26 SUPPLY CHAIN ANALYSIS
5.6.4 PRICING ANALYSIS
TABLE 5 AVERAGE SELLING PRICE OF LEADING PRODUCTS, BY KEY PLAYER (USD)
FIGURE 27 AVERAGE SELLING PRICE OF TOP 2 LEADING PRODUCTS, BY KEY PLAYER
5.6.4.1 Average selling price trend
TABLE 6 AVERAGE PRICE OF GLUCOSE MONITORING & CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022 (USD)
TABLE 7 AVERAGE PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022 (USD)
TABLE 8 AVERAGE PRICE OF OTHER POINT-OF-CARE TESTING PRODUCTS, BY COUNTRY, 2022 (USD)
5.7 PORTER’S FIVE FORCES ANALYSIS
TABLE 9 POINT OF CARE DIAGNOSTICS INDUSTRY: PORTER’S FIVE FORCES ANALYSIS
5.7.1 BARGAINING POWER OF BUYERS
5.7.2 BARGAINING POWER OF SUPPLIERS
5.7.3 THREAT OF NEW ENTRANTS
5.7.4 THREAT OF SUBSTITUTES
5.7.5 INTENSITY OF COMPETITIVE RIVALRY
5.8 TRADE DATA
TABLE 10 IMPORT DATA FOR MALARIA DIAGNOSTICS KITS (HS CODE 300211), BY COUNTRY, 2018-2021 (USD MILLION)
TABLE 11 EXPORT DATA FOR MALARIA DIAGNOSTICS KITS (HS CODE 300211), BY COUNTRY, 2018-2021 (USD MILLION)
5.9 REIMBURSEMENT SCENARIO
TABLE 12 KEY MEDICARE CLINICAL LAB FEE SCHEDULE (CLFS) CODES FOR COVID-19 TESTING
TABLE 13 MEDICARE HCPCS CODES FOR HIV TESTING
5.10 PATENT ANALYSIS
FIGURE 28 TOP 10 PATENT OWNERS FOR POINT-OF-CARE DIAGNOSTICS (JANUARY 2012-DECEMBER 2023)
5.10.1 ECOSYSTEM/MARKET MAP
FIGURE 29 ANALYSIS OF PARENT MARKET: IN VITRO DIAGNOSTICS MARKET
5.10.2 KEY CONFERENCES & EVENTS
TABLE 14 MARKET: LIST OF KEY CONFERENCES & EVENTS (2023−2024)
5.11 CASE STUDY ANALYSIS
5.11.1 DEVELOPMENT OF HIGH-SENSITIVITY TROPONIN I
TABLE 15 CASE 1: DIAGNOSING LOWER LEVELS OF TROPONIN IN CARDIAC PATIENTS
5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 30 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF POINT-OF-CARE TESTING KITS & INSTRUMENTS
TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR POINT-OF-CARE TESTING KITS AND INSTRUMENTS (%)
5.14 BUYING CRITERIA
FIGURE 32 KEY BUYING CRITERIA FOR POINT-OF-CARE TESTING KITS & INSTRUMENTS
TABLE 17 KEY BUYING CRITERIA FOR POC PRODUCTS

6 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE (Page No. - 90)
6.1 INTRODUCTION
TABLE 18 POINT OF CARE DIAGNOSTICS INDUSTRY, BY MODE OF PURCHASE, 2021-2028 (USD MILLION)
6.2 OTC TESTING PRODUCTS
6.2.1 GROWING PATIENT PREFERENCE FOR REMOTE HEALTHCARE TO PROPEL MARKET
TABLE 19 OTC TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
6.3 PRESCRIPTION-BASED TESTING PRODUCTS
6.3.1 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET
TABLE 20 PRESCRIPTION-BASED TESTING PRODUCTS MARKET, BY REGION, 2021-2028 (USD MILLION)

7 POINT OF CARE DIAGNOSTICS MARKET, BY PLATFORM (Page No. - 94)
7.1 INTRODUCTION
TABLE 21 POINT OF CARE DIAGNOSTICS INDUSTRY, BY PLATFORM, 2021-2028 (USD MILLION)
7.2 LATERAL FLOW ASSAYS
7.2.1 RISING ADOPTION OF TESTING PRODUCTS IN HOME CARE SETTINGS TO DRIVE MARKET
TABLE 22 MARKET FOR LATERAL FLOW ASSAYS, BY REGION, 2021-2028 (USD MILLION)
7.3 IMMUNOASSAYS
7.3.1 UTILIZATION IN INFECTIOUS DISEASE TESTING TO SUPPORT MARKET GROWTH
TABLE 23 MARKET FOR IMMUNOASSAYS, BY REGION, 2021-2028 (USD MILLION)
7.4 MICROFLUIDICS
7.4.1 GROWING TREND OF MINIATURIZATION AND RISING TECHNOLOGICAL ADVANCEMENTS TO PROPEL MARKET
TABLE 24 MARKET FOR MICROFLUIDICS, BY REGION, 2021-2028 (USD MILLION)
7.5 DIPSTICKS
7.5.1 QUALITATIVE ANALYSIS OF MEDICAL CONDITIONS TO SUPPORT MARKET GROWTH
TABLE 25 MARKET FOR DIPSTICKS, BY REGION, 2021-2028 (USD MILLION)
7.6 MOLECULAR DIAGNOSTICS
TABLE 26 MARKET FOR MOLECULAR DIAGNOSTICS, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 27 MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2021-2028 (USD MILLION)
7.6.1 RT-PCR
7.6.1.1 Rising cases of COVID-19 to boost demand
TABLE 28 MARKET FOR RT-PCR, BY REGION, 2021-2028 (USD MILLION)
7.6.2 INAAT
7.6.2.1 Cost benefits of INAAT to propel segment growth
TABLE 29 MARKET FOR INAAT, BY REGION, 2021-2028 (USD MILLION)
7.6.3 OTHER TECHNOLOGIES
TABLE 30 MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021-2028 (USD MILLION)

8 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE (Page No. - 103)
8.1 INTRODUCTION
TABLE 31 POINT OF CARE DIAGNOSTICS INDUSTRY, BY SAMPLE, 2021-2028 (USD MILLION)
8.2 BLOOD SAMPLES
8.2.1 HIGH UTILIZATION IN DISEASE DETECTION TO DRIVE MARKET
TABLE 32 MARKET FOR BLOOD SAMPLES, BY REGION, 2021-2028 (USD MILLION)
8.3 URINE SAMPLES
8.3.1 INCREASING PREVALENCE OF KIDNEY DISORDERS AND WIDE RANGE OF DIAGNOSTIC TARGETS TO BOOST DEMAND
TABLE 33 MARKET FOR URINE SAMPLES, BY REGION, 2021-2028 (USD MILLION)
8.4 NASAL & OROPHARYNGEAL SWABS
8.4.1 RISING INCIDENCE OF RESPIRATORY INFECTIONS TO PROPEL MARKET
TABLE 34 MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY REGION, 2021-2028 (USD MILLION)
8.5 OTHER SAMPLES
TABLE 35 MARKET FOR OTHER SAMPLES, BY REGION, 2021-2028 (USD MILLION)

9 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT (Page No. - 107)
9.1 INTRODUCTION
TABLE 36 POINT OF CARE DIAGNOSTICS INDUSTRY, BY PRODUCT, 2021-2028 (USD MILLION)
9.2 GLUCOSE MONITORING PRODUCTS
TABLE 37 MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 38 MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.2.1 STRIPS
9.2.1.1 Ability to provide single-use measurement testing to drive market
TABLE 39 GLUCOSE MONITORING STRIPS MARKET, BY REGION, 2021-2028 (USD MILLION)
9.2.2 METERS
9.2.2.1 Ability to adjust therapeutic regimens daily to support market growth
TABLE 40 GLUCOSE MONITORING METERS MARKET, BY REGION, 2021-2028 (USD MILLION)
9.2.3 LANCETS & LANCING DEVICES
9.2.3.1 Provision of multiple depth penetration settings to boost demand
TABLE 41 GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
9.3 COVID-19 TESTING PRODUCTS
9.3.1 RISING UPTAKE OF RT-PCR RAPID TESTS TO BOOST DEMAND
TABLE 42 MARKET FOR COVID-19 TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.4 CARDIOMETABOLIC MONITORING PRODUCTS
TABLE 43 MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 44 MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.4.1 CARDIAC MARKER TESTING PRODUCTS
9.4.1.1 Rising government initiatives for CVD research to drive market
TABLE 45 MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.4.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS
9.4.2.1 Technological advancements in monitoring products to support market growth
TABLE 46 MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.4.3 HBA1C TESTING PRODUCTS
9.4.3.1 Favorable clinical outcomes with long-term monitoring to drive market
TABLE 47 MARKET FOR HBA1C TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.5 INFECTIOUS DISEASE TESTING PRODUCTS
TABLE 48 MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 49 MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.5.1 HIV TESTING PRODUCTS
9.5.1.1 Rising prevalence of HIV to drive market
TABLE 50 MARKET FOR HIV TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.5.2 RESPIRATORY INFECTION TESTING PRODUCTS
9.5.2.1 Rising incidence of respiratory infections to drive market
TABLE 51 MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.5.3 HEPATITIS C TESTING PRODUCTS
9.5.3.1 Increasing prevalence of viral hepatitis to support market growth
TABLE 52 MARKET FOR HEPATITIS C TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.5.4 HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS
9.5.4.1 High incidence of UTIs and surgical-site infections to boost demand
TABLE 53 MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.5.5 INFLUENZA TESTING PRODUCTS
9.5.5.1 Ability to identify A & B viral nucleoprotein antigens to drive market
TABLE 54 MARKET FOR INFLUENZA TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.5.6 TROPICAL DISEASE TESTING PRODUCTS
9.5.6.1 Rising incidence of malaria and dengue to support market growth
TABLE 55 MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.5.7 SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS
TABLE 56 MARKET FOR STD TESTING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 57 MARKET FOR STD TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.5.7.1 Syphilis testing products
9.5.7.1.1 Introduction of rapid tests to boost demand
TABLE 58 DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.5.7.2 Human papillomavirus (HPV) testing products
9.5.7.2.1 Rising uptake of HPV diagnostics and RT-PCR to support market growth
TABLE 59 DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.5.7.3 Chlamydia trachomatis testing products
9.5.7.3.1 Growing awareness of STI detection to boost demand
TABLE 60 DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.5.7.4 Herpes simplex virus (HSV) testing products
9.5.7.4.1 Increasing incidence of HSV to support market growth
TABLE 61 DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.5.8 TUBERCULOSIS
9.5.8.1 Rising prevalence of TB in underserved areas to support market growth
TABLE 62 DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2021-2028 (USD MILLION)
9.5.9 CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS
9.5.9.1 Rising cases among hospitalized patients to boost demand
TABLE 63 DIAGNOSTICS MARKET FOR CDI, BY REGION, 2021-2028 (USD MILLION)
9.5.10 OTHER INFECTIOUS DISEASE TESTING PRODUCTS
TABLE 64 POINT OF CARE DIAGNOSTICS INDUSTRY FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.6 COAGULATION MONITORING PRODUCTS
TABLE 65 MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 66 MARKET FOR COAGULATION MONITORING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.6.1 PT/INR TESTING PRODUCTS
9.6.1.1 Ability to detect blood clots to support market growth
TABLE 67 DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.6.2 ACT/APTT TESTING PRODUCTS
9.6.2.1 Rising cases of dialysis and ESRD to boost demand
TABLE 68 DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.7 PREGNANCY & FERTILITY TESTING PRODUCTS
TABLE 69 MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 70 MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.7.1 PREGNANCY TESTING PRODUCTS
9.7.1.1 Growing preference for home care testing to drive market
TABLE 71 MARKET FOR PREGNANCY TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.7.2 FERTILITY TESTING PRODUCTS
9.7.2.1 Growing focus on family planning to boost demand
TABLE 72 MARKET FOR FERTILITY TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.8 TUMOR/CANCER MARKER TESTING PRODUCTS
9.8.1 INCREASING INCIDENCE OF CANCER AND RISING UPTAKE OF IMMUNOASSAYS TO PROPEL MARKET
TABLE 73 MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.9 URINALYSIS TESTING PRODUCTS
9.9.1 HIGH INCIDENCE OF RECURRENT UTIS TO DRIVE MARKET
TABLE 74 MARKET FOR URINALYSIS TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.10 CHOLESTEROL TESTING PRODUCTS
9.10.1 RISING OBESITY LEVELS AND INCIDENCE OF CVD TO BOOST DEMAND
TABLE 75 MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.11 HEMATOLOGY TESTING PRODUCTS
9.11.1 PREFERENCE FOR LABORATORY-BASED TESTS TO RESTRAIN MARKET
TABLE 76 MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2021-2028(USD MILLION)
9.12 DRUGS-OF-ABUSE TESTING PRODUCTS
9.12.1 RISING CONSUMPTION OF ILLICIT DRUGS TO FUEL MARKET
TABLE 77 MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.13 THYROID-STIMULATING HORMONE (TSH) TESTING PRODUCTS
9.13.1 RISING CASES OF THYROID TO BOOST DEMAND
TABLE 78 MARKET FOR TSH TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.14 FECAL OCCULT TESTING PRODUCTS
9.14.1 INCREASING AWARENESS ON EARLY DISEASE DETECTION TO SUPPORT MARKET GROWTH
TABLE 79 MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
9.15 OTHER PRODUCTS
TABLE 80 MARKET FOR OTHER PRODUCTS, BY REGION, 2021-2028 (USD MILLION)

10 POINT OF CARE DIAGNOSTICS MARKET, BY END USER (Page No. - 140)
10.1 INTRODUCTION
TABLE 81 POINT OF CARE DIAGNOSTICS INDUSTRY, BY END USER, 2021-2028 (USD MILLION)
10.2 CLINICAL LABORATORIES
10.2.1 IMPROVEMENTS IN AUTOMATED TESTING SERVICES TO BOOST DEMAND
TABLE 82 MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021-2028 (USD MILLION)
10.3 AMBULATORY CARE FACILITIES AND PHYSICIANS’ OFFICES
10.3.1 RAPID RESULT GENERATION AND AVAILABILITY OF IMMEDIATE PATIENT CARE TO DRIVE MARKET
TABLE 83 MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIANS’ OFFICES, BY REGION, 2021-2028 (USD MILLION)
10.4 PHARMACIES, RETAIL CLINICS, AND E-COMMERCE PLATFORMS
10.4.1 ABILITY TO SUPPORT CHRONIC DISEASE MANAGEMENT TO BOOST DEMAND
TABLE 84 MARKET FOR PHARMACIES, RETAIL CLINICS, AND E-COMMERCE PLATFORMS, BY REGION, 2021-2028 (USD MILLION)
10.5 HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS
10.5.1 RAPID RESULTS AND END USERS OF POC DIAGNOSTICS
TABLE 85 MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY REGION, 2021-2028 (USD MILLION)
10.6 HOME CARE SETTINGS AND SELF-TESTING
10.6.1 GROWING INCLINATION TOWARDS REMOTE-BASED CARE TO DRIVE MARKET
TABLE 86 MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY REGION, 2021-2028 (USD MILLION)
10.7 OTHER END USERS
TABLE 87 MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)

11 POINT OF CARE DIAGNOSTICS MARKET, BY REGION (Page No. - 147)
11.1 INTRODUCTION
TABLE 88 POINT OF CARE DIAGNOSTICS INDUSTRY, BY REGION, 2021-2028 (USD MILLION)
11.2 NORTH AMERICA
11.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 33 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET SNAPSHOT
TABLE 89 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 90 NORTH AMERICA: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 91 NORTH AMERICA: MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 92 NORTH AMERICA: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 93 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 94 NORTH AMERICA: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 95 NORTH AMERICA: MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 96 NORTH AMERICA: MARKET, BY PLATFORM, 2021-2028 (USD MILLION)
TABLE 97 NORTH AMERICA: MARKET, BY MODE OF PURCHASE, 2021-2028 (USD MILLION)
TABLE 98 NORTH AMERICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 99 NORTH AMERICA: MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
11.2.2 US
11.2.2.1 Favorable government support and medical reimbursements to boost demand
TABLE 100 US: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Rising incidence of diabetes and cancer to support market growth
TABLE 101 CANADA: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
11.3 EUROPE
11.3.1 EUROPE: RECESSION IMPACT
TABLE 102 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 103 EUROPE: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 104 EUROPE: MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 105 EUROPE: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 106 EUROPE: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 107 EUROPE: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 108 EUROPE: MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 109 EUROPE: MARKET, BY PLATFORM, 2021-2028 (USD MILLION)
TABLE 110 EUROPE: MARKET, BY MODE OF PURCHASE, 2021-2028 (USD MILLION)
TABLE 111 EUROPE: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 112 EUROPE: MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
11.3.2 GERMANY
11.3.2.1 Rising demand for innovative technologies to propel market
TABLE 113 GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Growing public-private collaborations for product development to drive market
TABLE 114 FRANCE: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
11.3.4 UK
11.3.4.1 Growing number of accredited diagnostic & hospital laboratories to propel market
TABLE 115 UK: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
11.3.5 ITALY
11.3.5.1 Increasing adoption of infectious disease diagnostics to drive market
TABLE 116 ITALY: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
11.3.6 SPAIN
11.3.6.1 Rising incidence of chronic diseases to support market growth
TABLE 117 SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 118 REST OF EUROPE: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
11.4 ASIA PACIFIC
11.4.1 ASIA PACIFIC: RECESSION IMPACT
FIGURE 34 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET SNAPSHOT
TABLE 119 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 120 ASIA PACIFIC: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 121 ASIA PACIFIC: MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 122 ASIA PACIFIC: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 123 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 124 ASIA PACIFIC: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 125 ASIA PACIFIC: MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 126 ASIA PACIFIC: MARKET, BY PLATFORM, 2021-2028 (USD MILLION)
TABLE 127 ASIA PACIFIC: MARKET, BY MODE OF PURCHASE, 2021-2028 (USD MILLION)
TABLE 128 ASIA PACIFIC: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 129 ASIA PACIFIC: MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
11.4.2 JAPAN
11.4.2.1 Availability of advanced rapid flu tests to drive market
TABLE 130 JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
11.4.3 CHINA
11.4.3.1 Rising incidence of infectious diseases to drive market
TABLE 131 CHINA: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
11.4.4 INDIA
11.4.4.1 High burden of chronic diseases to propel market
TABLE 132 INDIA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
11.4.5 AUSTRALIA
11.4.5.1 Increasing research investments for next-gen POC devices to fuel market
TABLE 133 AUSTRALIA: MARKET, BY PRODUCT, 2021-2028 (USD MILLION
11.4.6 SOUTH KOREA
11.4.6.1 Growing awareness about advanced POC devices to boost demand
TABLE 134 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
11.4.7 REST OF ASIA PACIFIC
TABLE 135 REST OF ASIA PACIFIC: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
11.5 LATIN AMERICA
11.5.1 LATIN AMERICA: RECESSION IMPACT
TABLE 136 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 137 LATIN AMERICA: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 138 LATIN AMERICA: MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 139 LATIN AMERICA: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 140 LATIN AMERICA: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 141 LATIN AMERICA: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 142 LATIN AMERICA: MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 143 LATIN AMERICA: MARKET, BY PLATFORM, 2021-2028 (USD MILLION)
TABLE 144 LATIN AMERICA: MARKET, BY MODE OF PURCHASE, 2021-2028 (USD MILLION)
TABLE 145 LATIN AMERICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 146 LATIN AMERICA: MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
11.5.2 BRAZIL
11.5.2.1 Rising prevalence of diabetes to support market growth
TABLE 147 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
11.5.3 MEXICO
11.5.3.1 Rising incidence of cancer to drive market
TABLE 148 MEXICO: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
11.5.4 REST OF LATIN AMERICA
TABLE 149 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
TABLE 150 MIDDLE EAST & AFRICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 151 MIDDLE EAST & AFRICA: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 152 MIDDLE EAST & AFRICA: MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 153 MIDDLE EAST & AFRICA: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 154 MIDDLE EAST & AFRICA: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 155 MIDDLE EAST & AFRICA: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 156 MIDDLE EAST & AFRICA: MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 157 MIDDLE EAST & AFRICA: MARKET, BY PLATFORM, 2021-2028 (USD MILLION)
TABLE 158 MIDDLE EAST & AFRICA: MARKET, BY MODE OF PURCHASE, 2021-2028 (USD MILLION)
TABLE 159 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 160 MIDDLE EAST & AFRICA: MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
11.6.1.1 GCC Countries
11.6.1.1.1 Improvements in healthcare infrastructure to drive market
TABLE 161 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
11.6.2 REST OF MIDDLE EAST & AFRICA
TABLE 162 REST OF AFRICA: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 163 REST OF MIDDLE EAST & AFRICA: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. - 208)
12.1 INTRODUCTION
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
FIGURE 35 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN POINT-OF-CARE DIAGNOSTICS MARKET
12.3 REVENUE SHARE ANALYSIS
FIGURE 36 REVENUE ANALYSIS OF TOP FIVE PLAYERS IN POINT OF CARE DIAGNOSTICS INDUSTRY (2022)
12.4 MARKET SHARE ANALYSIS
FIGURE 37 POINT OF CARE DIAGNOSTICS INDUSTRY SHARE, BY KEY PLAYER (2022)
12.5 COMPANY EVALUATION MATRIX
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 38 COMPANY EVALUATION MATRIX
12.5.5 COMPANY FOOTPRINT
12.5.5.1 Product & regional footprint
TABLE 164 OVERALL FOOTPRINT
TABLE 165 PRODUCT FOOTPRINT
TABLE 166 REGIONAL FOOTPRINT
12.6 START-UP/SME EVALUATION MATRIX
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
FIGURE 39 START-UP/SME EVALUATION MATRIX
12.6.5 COMPETITIVE BENCHMARKING
TABLE 167 POINT OF CARE DIAGNOSTICS INDUSTRY: DETAILED LIST OF KEY START-UPS/SMES
12.7 COMPETITIVE SCENARIO
12.7.1 PRODUCT LAUNCHES & APPROVALS
TABLE 168 POINT OF CARE DIAGNOSTICS INDUSTRY: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020-NOVEMBER 2023)
12.7.2 DEALS
TABLE 169 POINT OF CARE DIAGNOSTICS INDUSTRY: DEALS (JANUARY 2020-NOVEMBER 2023)
12.7.3 OTHER DEVELOPMENTS
TABLE 170 POINT OF CARE DIAGNOSTICS INDUSTRY: OTHER DEVELOPMENTS (JANUARY 2020-NOVEMBER 2023)

13 COMPANY PROFILES (Page No. - 223)
13.1 KEY PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1.1 ABBOTT LABORATORIES
TABLE 171 ABBOTT LABORATORIES: COMPANY OVERVIEW
FIGURE 40 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
13.1.2 F. HOFFMANN-LA ROCHE LTD.
TABLE 172 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
13.1.3 SIEMENS HEALTHINEERS
TABLE 173 SIEMENS HEALTHINEERS: COMPANY OVERVIEW
FIGURE 42 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2023)
13.1.4 QUIDELORTHO CORPORATION
TABLE 174 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
FIGURE 43 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
13.1.5 DANAHER CORPORATION
TABLE 175 DANAHER CORPORATION: COMPANY OVERVIEW
FIGURE 44 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
13.1.6 BECTON, DICKINSON AND COMPANY
TABLE 176 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
FIGURE 45 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
13.1.7 THERMO FISHER SCIENTIFIC INC.
TABLE 177 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
FIGURE 46 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
TABLE 178 PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS
13.1.8 BIOMÉRIEUX
TABLE 179 BIOMÉRIEUX : COMPANY OVERVIEW
FIGURE 47 BIOMÉRIEUX : COMPANY SNAPSHOT (2022)
13.1.9 CHEMBIO DIAGNOSTICS, INC.
TABLE 180 CHEMBIO DIAGNOSTICS, INC.: COMPANY OVERVIEW
FIGURE 48 CHEMBIO DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2022)
13.1.10 EKF DIAGNOSTICS HOLDINGS PLC
TABLE 181 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW
FIGURE 49 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2022)
13.1.11 TRINITY BIOTECH PLC
TABLE 182 TRINITY BIOTECH PLC: COMPANY OVERVIEW
FIGURE 50 TRINITY BIOTECH PLC: COMPANY SNAPSHOT (2022)
13.1.12 WERFEN, S.A.
TABLE 183 WERFEN: COMPANY OVERVIEW
FIGURE 51 WERFEN, S.A.: COMPANY SNAPSHOT (2022)
13.1.13 NOVA BIOMEDICAL
TABLE 184 NOVA BIOMEDICAL: COMPANY OVERVIEW
13.1.14 PTS DIAGNOSTICS
TABLE 185 PTS DIAGNOSTICS: COMPANY OVERVIEW
13.1.15 SEKISUI DIAGNOSTICS
TABLE 186 SEKISUI DIAGNOSTICS: COMPANY OVERVIEW
13.1.16 EUROLYSER DIAGNOSTICA GMBH
TABLE 187 EUROLYSER DIAGNOSTICA GMBH: COMPANY OVERVIEW
13.1.17 RESPONSE BIOMEDICAL
TABLE 188 RESPONSE BIOMEDICAL: COMPANY OVERVIEW
13.1.18 ALFA SCIENTIFIC DESIGNS, INC.
TABLE 189 ALFA SCIENTIFIC DESIGNS, INC: COMPANY OVERVIEW
13.1.19 BODITECH MED INC.
TABLE 190 BODITECH MED INC.: COMPANY OVERVIEW
13.1.20 BTNX INC.
TABLE 191 BTNX INC.: COMPANY OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS
13.2.1 LIFESCAN IP HOLDINGS, LLC
13.2.2 ASCENSIA DIABETES CARE HOLDINGS AG
13.2.3 FLUXERGY
13.2.4 PRECISION BIOSENSOR, INC.
13.2.5 ACON LABORATORIES, INC.
13.2.6 A. MENARINI DIAGNOSTICS S.R.L.
13.2.7 ORASURE TECHNOLOGIES, INC.
13.2.8 MANKIND PHARMA
13.2.9 GRIFOLS, S.A.
13.2.10 DIASORIN S.P.A.

14 APPENDIX (Page No. - 314)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS